Kidney cancer patients will not be permitted a new drug that possibly will extend their lives by no less than three months since the cost of financing such drugs is far more expensive, the NHS drug rationing body has said.

The National Institute for Health and Clinical Excellence has turned down the drug, which is called as everolimus, also known as Afinitor, saying it does not offer sufficient benefit to patients to give good reason for the cost.

Each pack of the drug costs £2,822 and the producer, Novartis, had presented the foremost pack free to the NHS and a five per cent concession on following ones.

But even with this, and taking into consideration new regulation on end of life drugs, which lets Nice to give approval to more expensive drugs that extend life for patients with unusual diseases, the treatment was still too costly to be borne, the panel settled.

The cost for each quality adjusted life year could gain, a multifaceted calculation taking into consideration upgrading in quality of life plus additional length of life against the cost of the new drug on top of on hand treatments, is approximately double what Nice would usually permit.